TPG, an alternative asset management firm, completed the investment in K2 Medical Research, an integrated clinical trial site platform specializing in central nervous system trials. Financial terms were not disclosed. “At the core of our healthcare investing strategy is to partner with and grow companies that are adding value to the healthcare system and enabling better patient outcomes. Through its important clinical research work, the team at K2 is delivering solutions that benefit patients, physicians, and the broader research community. We have known Sean for many years and look forward to partnering with him, Brandon, and the K2 team on this next phase of their growth journey," Matthew Hobart, Co-TPG Managing Partner.